Reports Q1 revenue $62.5M, consensus $61.06M. “We are pleased to report continued positive growth and momentum for LUPKYNIS in the first quarter of 2025 and are looking forward to a strong performance this year,” stated Peter Greenleaf, President and Chief Executive Officer of Aurinia. “Following the recent update to the American College of Rheumatology lupus nephritis treatment guideline, which recommends the incorporation of drugs like LUPKYNIS into first-line therapy, our commercial organization is focused on educating rheumatologists about the benefits of initiating LUPKYNIS earlier in the treatment paradigm. We also remain on track to report initial results from our Phase 1 study of AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand (APRIL), later this quarter.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUPH:
- Aurinia Pharmaceuticals Reports Strong First Quarter 2025 Financial Results
- Aurinia Pharmaceuticals to Announce Q1 2025 Results
- Glass Lewis Supports Aurinia’s Proposals for 2025 AGM
- Aurinia Pharmaceuticals’ proposals receive recommendation from Glass Lewis
- ISS Endorses Aurinia’s Proposals for 2025 Annual Meeting
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue